---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-096935"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:32:39.664725+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics treats first patient in Phase 1 OTS MAR-T cell study; well tolerated

## Summary
- First patient dosed at 100x10^6 cells in Phase 1 RAPID study evaluating MT-401 as Off-the-Shelf product.
- No treatment-related adverse events observed in first patient; safety consistent with prior MAR-T cell data.
- OTS product aims to accelerate time to treatment to as fast as 72 hours using healthy donor material.
- Non-dilutive funding from FDA, NIH SBIR, and CPRIT supports OTS program without affecting cash runway.
- APOLLO study in lymphoma reported 66% objective response rate and durable complete responses.

## SEC filing metadata
- accession: 0001104659-25-096935
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465925096935/0001104659-25-096935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465925096935/tm2527906d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-096935
- JSON: https://secwatch.observer/filing/0001104659-25-096935.json
- Plain text: https://secwatch.observer/filing/0001104659-25-096935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.